Zobrazeno 1 - 10
of 68
pro vyhledávání: ''
Autor:
Ulrich Jaeger, Marek Borsky, Jan Oppelt, Laura Z. Rassenti, Medhat Shehata, Václav Šeda, Thomas J. Kipps, Gabriela Pavlasova, Jennifer R. Brown, Daniel Filip, Kvetoslava Liskova, Šárka Pospíšilová, Eva Vojackova, Lenka Kostalova, Matthew S. Davids, Marek Mráz, Katerina Cerna, Sonali Sharma, Jiri Mayer, Andrea Janíková, Pedro Faria Zeni, Stacey M. Fernandes, Veronika Šandová, Laura Ondrisova, Michael Doubek, Leos Kren
Publikováno v:
Blood
B-cell receptor (BCR) signaling and T-cell interactions play a pivotal role in chronic lymphocytic leukemia (CLL) pathogenesis and disease aggressiveness. CLL cells can use microRNAs (miRNAs) and their targets to modulate microenvironmental interacti
Autor:
Mercedeh Tajdar, Helena Devos, Dominik Selleslag, Friedel Nollet, Pieter Van Vlierberghe, Louis Nevejan, Matthijs Vynck, Tom Lodewyck
Publikováno v:
Blood Adv
Clonal hematopoiesis (CH) is associated with age and an increased risk of myeloid malignancies, cardiovascular risk, and all-cause mortality. We tested for CH in a setting where hematopoietic stem cells (HSCs) of the same individual are exposed to di
Autor:
Vincent-Philippe Lavallée, Marie-Eve Bordeleau, Laura Simon, Geneviève Boucher, Josée Hébert, Chi-Yuan Yao, Jean-François Spinella, Sébastien Lemieux, Guy Sauvageau, Éric Audemard, Isabel Boivin
Publikováno v:
Blood. 135:1882-1886
RUNX1 is mutated in ∼10% of adult acute myeloid leukemia (AML). Although most RUNX1 mutations in this disease are believed to be acquired, they can also be germline. Indeed, germline RUNX1 mutations result in the well-described autosomal-dominant f
Autor:
Mario Cazzola, Alessandro M. Vannucchi, Chiara Paoli, Rossella Manfredini, Paola Guglielmelli, Elisa Rumi, Francesco Mannelli, Annalisa Pacilli, Sara Fiaccabrino, Giada Rotunno, Giada Brogi, Giovanni Barosi, Benedetta Sordi, Francesca Gesullo, Carmela Mannarelli, Ilaria M. Marone
Publikováno v:
Blood. 133:2802-2808
TO THE EDITOR: The discovery of prognostically informative mutations in patients with primary myelofibrosis (PMF)[1][1] prompted the development of mutation-enhanced risk scores.[2][2][⇓][3][⇓][4][⇓][5]-[6][6] Among these mutations, those in AS
Autor:
Ming Hou, Fangmiao Jing, Yang Liu, Tao Sun, Yajing Zhao, Hong-yu Zhao, Yu Hou, Hai Zhou, Lizhen Li, Ya-hui Ma, Panpan Han, Xinguang Liu, Ping Li, Jun Peng, Daqi Li
Publikováno v:
Blood. 133:730-742
Increased macrophage phagocytosis of antibody-coated platelets, as well as decreased numbers and/or impaired function of CD4+CD25+Foxp3+ regulatory T (Treg) cells, has been shown to participate in the pathogenesis of immune thrombocytopenia (ITP). Lo
Autor:
Olga Derman, Nadege Gitego, Seishi Ogawa, Shanisha Gordon-Mitchell, Tushar D. Bhagat, Armin Graber, Yanhua Wang, Matthias Bartenstein, Yun Mai, Amit Verma, Elaine Y. Chung, Aditi Shastri, Noah Kornblum, Ronald Rice, Lee Ratner, Kira Gritsman, Murali Janakiram, Urvi A Shah, Ira Braunschweig, B. Hilda Ye, Crystall Parrish, Gaurav Choudhary, Jeff Hall, Yongqiang Wei, Adam F. Binder, Ancy Joseph, Elise Ishida, Ioannis Mantzaris, Swati Goel, Keisuke Kataoka, Chirag K Bhagat, Orsolya Giricz, Kith Pradhan
Adult T-cell leukemia lymphoma (ATLL) is a rare T cell neoplasm that is endemic in Japanese, Caribbean, and Latin American populations. Most North American ATLL patients are of Caribbean descent and are characterized by high rates of chemo-refractory
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b84bd800943fe10df30123821e3ceaac
https://europepmc.org/articles/PMC6410908/
https://europepmc.org/articles/PMC6410908/
Autor:
Wei Wang, Pei Lin, Hagop M. Kantarjian, Michael W. Beaty, Jorge E. Cortes, Shimin Hu, L. Jeffrey Medeiros, Timothy J. McDonnell, Di Ai, Hesham M. Amin, Chi Young Ok
Publikováno v:
Blood. 126:1699-1706
Chromosome 3q26.2 abnormalities in acute myeloid leukemia, including inv(3)/t(3;3) and t(3;21), have been studied and are associated with a poor prognosis. Their prevalence, response to tyrosine kinase inhibitor (TKI) treatment, and prognostic signif
Autor:
Mark Douglas, David T. Weaver, Adam Officer, David M. Weinstock, Yasuhiro Oki, Virginia Kelly, Steven M. Horwitz, Megan Perez, Jacob D. Jaffe, Patrick Kelly, Alison J. Moskowitz, Howard M. Stern, Sara N. Morrow, Francine M. Foss, Kerstin Allen, Patricia L. Myskowski, Pierluigi Porcu, Jon C. Aster, Jennifer Sweeney, Raphael Koch
Duvelisib (IPI-145) is an oral inhibitor of phosphatidylinositol 3-kinase (PI3K)-δ/γ isoforms currently in clinical development. PI3K-δ/γ inhibition may directly inhibit malignant T-cell growth, making duvelisib a promising candidate for patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7cb5e8f1c3d3b61e115071321dddad9
https://europepmc.org/articles/PMC5824337/
https://europepmc.org/articles/PMC5824337/
Publikováno v:
Blood. 132:1631-1632
Duodenal-type follicular lymphoma (DTFL) is a rare and highly indolent follicular lymphoma (FL) variant. It is morphologically and immunophenotypically indistinguishable from typical FL, characterized by restricted involvement of intestinal mucosa, a
Autor:
David J. Inwards, Patrick B. Johnston, Betsy LaPlant, Luis F. Porrata, Han W. Tun, Thomas M. Habermann, Grzegorz S. Nowakowski, Joseph P. Colgan, Svetomir N. Markovic, Mamta Gupta, Stephen M. Ansell, William R. Macon, Ivana N. Micallef, Thomas E. Witzig, Mary Stenson, Jing Jing Han, Craig B. Reeder
Publikováno v:
Blood. 126:328-335
Everolimus is an oral agent that targets the mammalian target of rapamycin (mTOR) pathway. This study investigated mTOR pathway activation in T-cell lymphoma (TCL) cell lines and assessed antitumor activity in patients with relapsed/refractory TCL in